# Louis Licamele

> Louis Licamele, PhD is a computer scientist turned drug developer who serves as Chief Development Officer and EVP of Clinical and Data Science at Bloom Science, a San Diego biotech building microbiome-based, ketogenic-mimicking live biotherapeutics for obesity and neurological disease. A founding team member, he oversees biostatistics, clinical data management, and data-driven trial design for the company's lead candidate BL-001. He built his career at the intersection of data and medicine - a BS in biology and computer science from Georgetown, a PhD in computer science from the University of Maryland, and senior informatics and biometrics roles at Vanda Pharmaceuticals and REGENXBIO. He also runs The Licamele Group, advising healthcare companies on data science, AI, and regulatory strategy.

- **Role:** Chief Development Officer & EVP of Clinical and Data Science at Bloom Science, Inc.
- **Organizations:** Bloom Science, Inc., The Licamele Group, REGENXBIO Inc., Vanda Pharmaceuticals, University of Maryland
- **Nationality:** American
- **Education:** BS, Biology & Computer Science, Georgetown University, PhD, Computer Science (also MA), University of Maryland
- **Known for:** Founding team member and Chief Development Officer of Bloom Science, Over two decades leading therapeutic development from discovery through Phase 3 and successful NDA submissions, Google Scholar record of ~1,473 citations, h-index 16, i10-index 21

## Career timeline

- **—** — Earned BS in Biology & Computer Science from Georgetown University
- **—** — Graduate Research Assistant in Computer Science at the University of Maryland; earned MA and PhD
- **—** — VP of Informatics at Vanda Pharmaceuticals, leading data and analytics through Phase 3 and NDA submissions
- **—** — VP of Biometrics at REGENXBIO, leading biostatistics, clinical data management, and clinical innovation
- **—** — Founded The Licamele Group, advising healthcare companies on data science, AI, and regulatory strategy
- **—** — Joined Bloom Science as a founding team member and Chief Development Officer / EVP of Clinical and Data Science
- **2025** — Bloom Science reports positive Phase 1 data for BL-001 showing durable weight loss in overweight adults
- **2026** — Bloom Science initiates Phase 1b obesity trial of BL-001, first patient dosed February 24, 2026

## Achievements

- Founding team member and Chief Development Officer of Bloom Science
- Over two decades leading therapeutic development from discovery through Phase 3 and successful NDA submissions
- Google Scholar record of ~1,473 citations, h-index 16, i10-index 21
- Contributed to pharmacogenomic research on antipsychotic response (iloperidone / NPAS3, QT prolongation)
- Contributed to the SET and RESET Phase 3 program for tasimelteon in non-24-hour sleep-wake disorder in blind patients
- Built data-driven patient identification methods for clinical trial recruitment

## Latest updates

- **2026-02** — Bloom Science dosed its first patient in the Phase 1b obesity trial of BL-001, positioning the program as a differentiated approach beyond GLP-1 drugs.
- **2025** — Bloom Science reported statistically significant, durable weight loss from the Phase 1 trial of BL-001 in overweight individuals.

## Links

- Website: https://bloomscience.com
- LinkedIn: https://www.linkedin.com/in/louislicamele/

---

Profile page: https://yespress.io/louis-licamele
Published by YesPress — https://yespress.io
Last updated: 2026-07-01